Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment

Who is this study for? People with HIV-1 who inject opiates and are initiating antiretroviral therapy
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut. The overall objective of this study is to define the impact of long-term mu-opiate receptor stimulation or blockage with medication for opiate use disorder (i.e, methadone, buprenorphine/naloxone, or extended-release naltrexone) on the kinetics and extent of immune reconstitution on HIV-1 infected people who inject opiate and initiating antiretroviral therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Meet DSM-5 criteria for moderate to severe opiate use disorder (as determined by DSM-5 checklist)

• Opiate use with a positive urine drug screen for heroin or other opiates (other than methadone, buprenorphine, buprenorphine/naloxone) at screening visit

• Documented HIV-1 infection with CD4 less than 350 cells/ μL and VL more than 10,000 copies/mL

• cART-naïve or or on cART no longer than 3 months if already started

• Willingness to receive cART or on cART no longer than 3 months if already started

• Willingness to be randomized to either daily methadone, buprenorphine/naloxone or monthly injection of extended-release naltrexone treatment

• Ability to understand and complete study procedures

• Provision of adequate locator information that lists all contact information a participant agrees that the research staff may use to reach him/her

• All participants must be able to comprehend the purpose of the study and to provide informed consent

• Is, in the opinion of the study physician, in stable health as determined by pre-study physical examination, medical history, ECG, and laboratory evaluations and is likely to complete the study.

• Has a total body weight of more than 50 kg (110 pounds) and a body mass index (BMI) of more than 20 at screening.

• Female subjects: Cannot be pregnant, Cannot be lactating, Must be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal defined as 1 year without bleeding or spotting) OR must agree to use an acceptable method of birth control (e.g., birth control pills, intrauterine device \[IUD\], or a double barrier method of birth control (condoms and spermicide together; or diaphragm, condom and spermicide together)

Locations
United States
Pennsylvania
University of Pennsylvania
ACTIVE_NOT_RECRUITING
Philadelphia
Other Locations
Viet Nam
Go Vap Clinic
RECRUITING
Ho Chi Minh City
Contact Information
Primary
David S Metzger, PhD
dsm@pennmedicine.upenn.edu
2157467346
Backup
Cecile M Denis, PhD
cdenis@pennmedicine.upenn.edu
2158981825
Time Frame
Start Date: 2023-01-30
Estimated Completion Date: 2025-06-30
Participants
Target number of participants: 225
Treatments
Experimental: Methadone
Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
Experimental: Buprenorphine/naloxone
Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
Experimental: XR-Naltrexone
Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
Related Therapeutic Areas
Sponsors
Collaborators: Ho Chi Minh City CDC, National Institute of Drug Abuse, The Wistar Institute, Institute of Applied Medicine and Epidemiology (IMEA)
Leads: University of Pennsylvania

This content was sourced from clinicaltrials.gov

Similar Clinical Trials